| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02395848 | Clostridium Difficile Infection | Drug: Fidaxomicin | McMaster University | Phase 3 | 2015-07-01 | 2016-04-12 |
| NCT01552668 | Clostridium Difficile Infection | Drug: Fidaxomicin|Drug: Placebo | Washington University School of Medicine|Centers for Disease Control and Prevention | Phase 4 | 2012-09-01 | 2014-05-27 |
| NCT02214771 | Clostridium Difficile Infection | Drug: Fidaxomicin|Drug: Treatment for CDI other than fidaxomicin Type | Astellas Pharma S.A.S.|Astellas Pharma Inc | | 2014-09-01 | 2016-09-14 |
| NCT02083627 | Drug-Drug Interaction (DDI)|Intestinal Absorption|Healthy Subjects|Pharmacokinetics of Rosuvastatin|Pharmacokinetics of Fidaxomicin | Drug: rosuvastatin|Drug: fidaxomicin | Astellas Pharma Europe B.V.|Cubist Pharmaceuticals LLC|Astellas Pharma Inc | Phase 1 | 2013-02-01 | 2014-05-19 |
| NCT01813448 | Pharmacokinetics of Fidaxomicin|Healthy Subjects | Drug: Fidaxomicin|Drug: Placebo | Astellas Pharma Global Development, Inc.|Cubist Pharmaceuticals LLC|Astellas Pharma Inc | Phase 1 | 2013-02-01 | 2014-05-19 |
| NCT01591863 | Clostridium Difficile-associated Diarrhea | Drug: fidaxomicin | Optimer Pharmaceuticals LLC | Phase 2 | 2012-06-01 | 2016-04-06 |
| NCT01818141 | Clostridium Difficile Infection | Drug: Vancomycin|Drug: Fidaxomicin | Hartford Hospital|Optimer Pharmaceuticals LLC | Phase 4 | 2012-08-01 | 2013-03-21 |
| NCT02692651 | Clostridium Difficile Infection (CDI) | Drug: Fidaxomicin|Drug: Vancomycin | University of Michigan|Merck Sharp & Dohme Corp. | Phase 4 | 2017-04-01 | 2017-03-21 |
| NCT02437591 | Inflammatory Bowel Disease (IBD)|Clostridium Difficile Infection (CDI) | Drug: fidaxomicin | Astellas Pharma Europe Ltd.|Merck Sharp & Dohme Corp.|Astellas Pharma Inc | Phase 4 | 2015-06-01 | 2017-03-17 |
| NCT01691248 | Clostridium Difficile-Associated Diarrhea (CDAD) | Drug: fidaxomicin|Drug: Placebo | Optimer Pharmaceuticals LLC | Phase 3 | 2012-10-01 | 2016-03-11 |
| NCT02461901 | Clostridium Difficile Infection | Other: Environmental sampling|Other: Skin swab sampling|Other: Fecal sampling | Professor Mark Wilcox|Astellas Pharma Europe Ltd.|The Leeds Teaching Hospitals NHS Trust|St George's Healthcare NHS Trust|University of Leeds | | 2015-01-01 | 2016-05-13 |
| NCT02218372 | Clostridium Difficile-associated Diarrhea (CDAD) | Drug: Fidaxomicin|Drug: Vancomycin | Astellas Pharma Europe B.V.|Merck Sharp & Dohme Corp.|Astellas Pharma Inc | Phase 3 | 2014-10-01 | 2017-02-01 |
| NCT00314951 | Clostridium Infections|Diarrhea | Drug: Fidaxomicin|Drug: Vancomycin|Drug: Matching Placebo to Fidaxomicin | Optimer Pharmaceuticals LLC | Phase 3 | 2006-05-01 | 2016-06-07 |
| NCT02464306 | Clostridium Difficile Infection|Solid Organ Transplant | Drug: fidaxomicin | University of Colorado, Denver | Phase 4 | 2016-12-01 | 2016-06-15 |
| NCT02355938 | Clostridium Difficile|Spinal Cord Injury | Drug: Fidaxomicin 200 mg|Drug: Placebo|Drug: Vancomycin | Baylor College of Medicine|Cubist Pharmaceuticals LLC | Phase 4 | 2014-02-01 | 2016-10-12 |
| NCT02254967 | Clostridium Difficile | Drug: Fidaxomicin|Drug: Vancomycin | Astellas Pharma Europe Ltd.|Merck Sharp & Dohme Corp.|Astellas Pharma Inc | Phase 4 | 2014-10-01 | 2016-11-01 |
| NCT01775397 | Clostridium Difficile | Drug: Fidaxomicin|Drug: Vancomycin|Drug: Placebo | Astellas Pharma Europe Ltd.|Cubist Pharmaceuticals LLC|Astellas Pharma Inc | Phase 4 | 2012-11-01 | 2014-06-02 |
| NCT02784002 | Clostridium Difficile Infection | Drug: Ridinilazole|Drug: Fidaxomicin | Summit Therapeutics | Phase 2 | 2014-12-01 | 2016-08-02 |
| NCT01533844 | Clostridium Difficile | | Astellas Pharma Europe B.V.|Astellas Pharma Inc | | 2012-03-01 | 2015-03-03 |
| NCT02057198 | C. Difficile|Diarrhea|Enterocolitis | Drug: Fidaxomicin|Drug: Metronidazole|Drug: Vancomycin | Duke University | Phase 4 | 2014-02-01 | 2016-08-31 |
